title: Wound healing complications in brain tumor patients on Bevacizumab.
abstract: Bevacizumab (BEV) is commonly used for treating recurrent glioblastoma (GBM), and wound healing is a well-established adverse event. Retrospective analysis of GBM patients with and without wound healing complications while on BEV treatment is reported. 287 patients identified, majority were males (60 %) with median age of 52.5 years. 14 cases identified with wound healing problems, related to either craniotomy (n = 8) or other soft tissue wounds (n = 6). Median duration of BEV treatment to complication was 62 days (range 6-559). Majority received 10 mg/kg (n = 11) and nine (64.3 %) were on corticosteroids, with median daily dose of 6 mg (range 1-16 mg) for median of 473 days before starting BEV. For dehisced craniotomy wounds, median time for starting BEV from last surgery was 29 days (range 27-345). Median time from starting BEV to developing wound complication was 47 days (range 16-173). Seven (87.5 %) had infected wounds requiring antibiotics, hospitalization. Four (50 %) required plastic surgery. BEV stopped and safely resumed in 6 (75 %) patients; median delay was 70 days (range 34-346). Soft tissue wounds included decubitus ulcer, dehisced striae, herpes simplex, trauma to hand and back, and abscess. Median time from starting BEV to wound issues was 72 days (range 6-559). Five (83.3 %) were infected, requiring antibiotics. While three (50 %) required hospitalization, none required plastic surgery. Treatment stopped in five (83.3 %) and restarted in two (median delay 48 days, range 26-69). Wound healing complications are uncommon but associated with significant morbidity. Identifying those at risk and contributing factors warrants further investigation.
authors: The University of Texas Health Science Center at Houston - School of Nursing, 6901 Bertner Ave, Houston, TX, 77030, USA. harshad.ladha@gmail.com.
authors: Harshad
authors: H
authors: Ladha
authors: The University of Texas Health Science Center at Houston - School of Nursing, 6901 Bertner Ave, Houston, TX, 77030, USA.
authors: Tushar
authors: T
authors: Pawar
authors: UT MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
authors: Mark R
authors: MR
authors: Gilbert
authors: Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.
authors: Jacob
authors: J
authors: Mandel
authors: UT MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
authors: Barbara
authors: B
authors: O-Brien
authors: UT MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
authors: Charles
authors: C
authors: Conrad
authors: UT MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
authors: Margaret
authors: M
authors: Fields
authors: UT MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
authors: Teresa
authors: T
authors: Hanna
authors: UT MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
authors: Carolyn
authors: C
authors: Loch
authors: The University of Texas Health Science Center at Houston - School of Nursing, 6901 Bertner Ave, Houston, TX, 77030, USA.|UT MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
authors: Terri S
authors: TS
authors: Armstrong
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D057286:Electronic Health Records / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects*; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab
keywords: Adverse events; Anti-angiogenic inhibitors; Bevacizumab; Brain tumors; Wound complications